BiotechTube
MitoSense

MitoSense

San Diego, United States· Est.
mitosenseinc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MitoSense is a private, preclinical-stage biotech founded in 2017, pioneering a first-in-class cellular biotherapy based on transplanting functional mitochondria. Its lead focus is on Amyotrophic Lateral Sclerosis (ALS), with potential applications across a broad spectrum of neurodegenerative disorders. The company leverages an experienced leadership team and is built upon foundational research by Dr. Robert Elliott, positioning it to address major unmet medical needs in a large and growing market.

Neurodegenerative Diseases

Technology Platform

Mitochondria Organelle Transplantation (MOT™) - a proprietary cellular biotherapy platform involving the isolation and transplantation of functional mitochondria into diseased cells to restore cellular energy production and function.

Opportunities

MitoSense operates in a massive, underserved market of neurodegenerative diseases with no cures.
Its first-in-class MOT™ platform, if clinically validated, could become a foundational treatment for multiple indications, creating significant value.
Early proof-of-concept data and exclusive IP provide a potential first-mover advantage in mitochondrial transplantation therapy.

Risk Factors

The company faces extreme scientific risk as its novel mitochondrial transplantation approach is unproven in humans.
As a pre-revenue, private company, it carries high financial risk and will require substantial capital to reach clinical trials.
Regulatory pathways for such a novel cellular therapy are complex and uncertain.

Competitive Landscape

While MitoSense claims no other therapy exactly like MOT™ exists, the broader field of mitochondrial medicine is active. Competitors include companies developing small molecules, gene therapies, and other modalities to improve mitochondrial function (e.g., Stealth BioTherapeutics, Astellas's Mitobridge). MitoSense's direct transplantation approach is a distinct and more invasive strategy.

More companies in Cell & Gene Therapy →More companies in United States →